Compare Crowdstrike Holdings Inc (CRWD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs ResMed Inc. — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Crowdstrike Holdings Inc is far larger — about 8.4× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and ResMed Inc. for 51 Days on average.
| CRWD | RMD | |
|---|---|---|
Market Cap | $269.31B | $31.89B |
Volume | 9,381,560 | 618,314 |
Sector | Technology | Health |
52-Week High | $278.86 | $275.96 |
52-Week Low | $87.56 | $182.82 |
Typical Hold Time | 97 Days | 51 Days |
Enterprise Value | $265.11B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% today but near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue growth remains robust at $3.95B for 2025, though profitability is challenged with a net margin of -0.49%. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $239.38 consensus target, while recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
Outlook remains favorable given CrowdStrike's leadership in AI-native cybersecurity and expanding market opportunities. However, elevated valuation multiples (P/S 49.86) and competitive pressures present risks. The stock's proximity to all-time highs suggests near-term consolidation potential, but long-term growth prospects in cybersecurity remain compelling.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
